Physician profile
Erik Jon Entin
NPI 1861477820
$2,146.91
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,263 · 2020: $396 · 2021: $475 · 2022: $13.28.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $462.88 | 2019-2020 | |
| Allergan, INC. | $310.57 | 2019-2021 | |
| Abbvie INC. | $309.12 | 2021-2022 | |
| Emd Serono, INC. | $208.57 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $143.17 | 2019-2021 | |
| Boston Scientific Corporation | $128.14 | 2019 | |
| Kyowa Kirin, INC. | $124.99 | 2019 | |
| Avanir Pharmaceuticals, INC. | $117.39 | 2020 | |
| Acorda Therapeutics, INC | $108.00 | 2019 | |
| Mdd US Operations, LLC | $66.60 | 2019-2020 | |
| Medtronic USA, INC. | $31.76 | 2019 | |
| Vertical Pharmaceuticals, LLC | $27.22 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $24.48 | 2021 | |
| Janssen Pharmaceuticals, INC | $21.76 | 2021 | |
| Adamas Pharmaceuticals, INC. | $20.30 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $14.87 | 2021 | |
| Abbott Laboratories | $14.65 | 2021 | |
| Alexion Pharmaceuticals, INC. | $12.44 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Entin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.